UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000023009 |
|---|---|
| Receipt number | R000026438 |
| Scientific Title | Phase 2b study of combined immunotherapy with dinutuximab, interleukin-2, and G-CSF for high risk neuroblastoma |
| Date of disclosure of the study information | 2016/07/04 |
| Last modified on | 2020/02/04 22:37:37 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2016/07/04 16:18:52 | ||
| 2 | Update | 2016/11/21 20:09:57 | Institutions |
|
| 3 | Update | 2016/11/21 20:11:15 | Recruitment status |
|
| 4 | Update | 2016/12/06 15:38:43 | Institutions |
|
| 5 | Update | 2018/01/04 10:16:56 | Recruitment status |
|
| 6 | Update | 2018/07/09 17:15:06 | ||
| 7 | Update | 2019/07/08 12:56:13 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Last name of contact person Last name of contact person Zip code Organization Organization Address Address Tel Institutions |
|
| 8 | Update | 2020/02/04 22:31:49 | Number of participants that the trial has enrolled |
|
| 9 | Update | 2020/02/04 22:37:37 | Recruitment status Date of IRB Last follow-up date |
